 Thomas Parker
Concepts (210)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Circulation | 17 | 2006 | 407 | 1.230 |
Why?
| | Neonatology | 3 | 2017 | 17 | 1.110 |
Why?
| | Parental Leave | 1 | 2022 | 17 | 0.830 |
Why?
| | Fellowships and Scholarships | 2 | 2022 | 227 | 0.770 |
Why?
| | Nitric Oxide Synthase | 13 | 2006 | 209 | 0.760 |
Why?
| | Sheep | 32 | 2010 | 764 | 0.710 |
Why?
| | Fetus | 17 | 2005 | 699 | 0.660 |
Why?
| | Intensive Care, Neonatal | 1 | 2018 | 39 | 0.620 |
Why?
| | Education, Medical, Graduate | 2 | 2022 | 368 | 0.600 |
Why?
| | Communication Barriers | 1 | 2018 | 89 | 0.590 |
Why?
| | Nitric Oxide | 15 | 2010 | 823 | 0.550 |
Why?
| | Vasodilation | 12 | 2005 | 419 | 0.500 |
Why?
| | Parents | 2 | 2022 | 1186 | 0.480 |
Why?
| | Lung | 17 | 2006 | 3558 | 0.450 |
Why?
| | Ductus Arteriosus | 9 | 2005 | 67 | 0.420 |
Why?
| | Hypertension, Pulmonary | 12 | 2005 | 1727 | 0.410 |
Why?
| | Pulmonary Artery | 9 | 2005 | 1015 | 0.410 |
Why?
| | Estradiol | 3 | 2000 | 455 | 0.400 |
Why?
| | Clinical Competence | 3 | 2017 | 893 | 0.380 |
Why?
| | Vascular Resistance | 8 | 2006 | 337 | 0.380 |
Why?
| | Nitric Oxide Synthase Type III | 7 | 2010 | 184 | 0.320 |
Why?
| | Internship and Residency | 2 | 2017 | 926 | 0.300 |
Why?
| | Amides | 2 | 2006 | 86 | 0.300 |
Why?
| | Curriculum | 1 | 2013 | 819 | 0.290 |
Why?
| | Animals, Newborn | 7 | 2005 | 778 | 0.280 |
Why?
| | Pediatrics | 1 | 2013 | 979 | 0.250 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2005 | 40 | 0.250 |
Why?
| | Sulfones | 1 | 2005 | 97 | 0.230 |
Why?
| | Vasoconstriction | 2 | 2005 | 177 | 0.230 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2006 | 386 | 0.220 |
Why?
| | Hemodynamics | 16 | 2006 | 1012 | 0.220 |
Why?
| | Endothelium, Vascular | 4 | 2006 | 843 | 0.220 |
Why?
| | Fetal Growth Retardation | 4 | 2010 | 467 | 0.200 |
Why?
| | Oxygen | 7 | 2004 | 854 | 0.190 |
Why?
| | Infant, Newborn | 11 | 2018 | 5043 | 0.180 |
Why?
| | Nitroarginine | 6 | 2006 | 47 | 0.180 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 4620 | 0.160 |
Why?
| | Gestational Age | 9 | 2010 | 759 | 0.150 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2003 | 329 | 0.150 |
Why?
| | Blood Vessels | 1 | 2000 | 180 | 0.150 |
Why?
| | Animals | 33 | 2010 | 31694 | 0.140 |
Why?
| | Pregnancy | 13 | 2010 | 5517 | 0.140 |
Why?
| | Bronchodilator Agents | 3 | 2007 | 239 | 0.140 |
Why?
| | Delphi Technique | 1 | 2017 | 160 | 0.140 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2018 | 176 | 0.140 |
Why?
| | Language | 1 | 2018 | 262 | 0.130 |
Why?
| | Epoprostenol | 1 | 1997 | 133 | 0.130 |
Why?
| | Enzyme Inhibitors | 5 | 2006 | 750 | 0.130 |
Why?
| | Physician's Role | 1 | 2017 | 197 | 0.130 |
Why?
| | High-Frequency Ventilation | 3 | 2000 | 41 | 0.130 |
Why?
| | Persistent Fetal Circulation Syndrome | 2 | 2007 | 132 | 0.120 |
Why?
| | Infant, Newborn, Diseases | 1 | 1997 | 104 | 0.120 |
Why?
| | Muscle, Smooth, Vascular | 3 | 2005 | 411 | 0.120 |
Why?
| | Administration, Inhalation | 9 | 2007 | 641 | 0.120 |
Why?
| | Antihypertensive Agents | 2 | 2000 | 429 | 0.120 |
Why?
| | Placenta | 4 | 2010 | 625 | 0.120 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2005 | 498 | 0.110 |
Why?
| | Physician Executives | 1 | 2013 | 33 | 0.110 |
Why?
| | United States | 2 | 2022 | 12176 | 0.100 |
Why?
| | Pulmonary Gas Exchange | 5 | 2005 | 117 | 0.100 |
Why?
| | Endothelin-1 | 4 | 2000 | 167 | 0.100 |
Why?
| | Data Collection | 1 | 2013 | 620 | 0.090 |
Why?
| | Education | 1 | 2011 | 95 | 0.090 |
Why?
| | RNA, Messenger | 4 | 2010 | 2552 | 0.090 |
Why?
| | Disease Models, Animal | 8 | 2010 | 3531 | 0.090 |
Why?
| | Humans | 15 | 2022 | 114623 | 0.080 |
Why?
| | Endothelin Receptor Antagonists | 3 | 2000 | 58 | 0.080 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 157 | 0.080 |
Why?
| | Colorado | 1 | 2018 | 4099 | 0.080 |
Why?
| | Blotting, Western | 5 | 2007 | 1147 | 0.080 |
Why?
| | Female | 15 | 2018 | 59466 | 0.080 |
Why?
| | Umbilical Arteries | 2 | 2006 | 41 | 0.080 |
Why?
| | Respiratory Distress Syndrome, Newborn | 2 | 1999 | 101 | 0.070 |
Why?
| | Hyaline Membrane Disease | 2 | 1998 | 20 | 0.070 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2010 | 398 | 0.070 |
Why?
| | Fluorocarbons | 2 | 1999 | 94 | 0.070 |
Why?
| | Prospective Studies | 1 | 2018 | 6217 | 0.070 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2007 | 122 | 0.070 |
Why?
| | 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 1 | 2006 | 27 | 0.070 |
Why?
| | Fetal Diseases | 2 | 2004 | 147 | 0.070 |
Why?
| | Attitude of Health Personnel | 1 | 2013 | 975 | 0.070 |
Why?
| | Ligation | 3 | 2002 | 75 | 0.060 |
Why?
| | Vasodilator Agents | 3 | 2003 | 302 | 0.060 |
Why?
| | rho-Associated Kinases | 1 | 2006 | 80 | 0.060 |
Why?
| | Uterus | 2 | 2006 | 192 | 0.060 |
Why?
| | Hypertension | 2 | 2005 | 1056 | 0.060 |
Why?
| | Positive-Pressure Respiration | 2 | 2003 | 68 | 0.060 |
Why?
| | Immunohistochemistry | 4 | 2006 | 1629 | 0.060 |
Why?
| | Regional Blood Flow | 3 | 2006 | 424 | 0.060 |
Why?
| | Respiration Disorders | 1 | 2005 | 69 | 0.060 |
Why?
| | Endothelin B Receptor Antagonists | 1 | 2004 | 11 | 0.060 |
Why?
| | Drug Combinations | 1 | 2005 | 287 | 0.060 |
Why?
| | Child | 1 | 2022 | 18404 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2006 | 1842 | 0.060 |
Why?
| | Young Adult | 1 | 2018 | 10455 | 0.060 |
Why?
| | Receptors, Endothelin | 2 | 2000 | 49 | 0.060 |
Why?
| | Vasomotor System | 2 | 2002 | 39 | 0.050 |
Why?
| | Superoxide Dismutase | 1 | 2005 | 305 | 0.050 |
Why?
| | Piperidines | 2 | 2004 | 160 | 0.050 |
Why?
| | Respiration, Artificial | 4 | 2001 | 529 | 0.050 |
Why?
| | Blotting, Northern | 2 | 2000 | 193 | 0.050 |
Why?
| | Embryonic and Fetal Development | 2 | 2000 | 94 | 0.050 |
Why?
| | Neovascularization, Pathologic | 1 | 2004 | 281 | 0.050 |
Why?
| | Hernia, Diaphragmatic | 1 | 2003 | 67 | 0.050 |
Why?
| | Oligopeptides | 2 | 2004 | 236 | 0.050 |
Why?
| | Pyridines | 1 | 2006 | 425 | 0.050 |
Why?
| | Endothelial Growth Factors | 1 | 2002 | 50 | 0.050 |
Why?
| | Lymphokines | 1 | 2002 | 111 | 0.050 |
Why?
| | Fatal Outcome | 2 | 2007 | 284 | 0.050 |
Why?
| | Pulmonary Alveoli | 1 | 2004 | 373 | 0.050 |
Why?
| | Blood Gas Analysis | 2 | 2000 | 72 | 0.050 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2003 | 129 | 0.050 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2002 | 351 | 0.050 |
Why?
| | Labor, Obstetric | 1 | 2001 | 52 | 0.050 |
Why?
| | Protein Kinase Inhibitors | 1 | 2006 | 785 | 0.040 |
Why?
| | Plethysmography | 1 | 2001 | 103 | 0.040 |
Why?
| | Hernias, Diaphragmatic, Congenital | 1 | 2003 | 186 | 0.040 |
Why?
| | Endothelins | 1 | 2000 | 61 | 0.040 |
Why?
| | Physical Stimulation | 1 | 2000 | 77 | 0.040 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2000 | 141 | 0.040 |
Why?
| | Muscle, Smooth | 1 | 2000 | 144 | 0.040 |
Why?
| | Receptor, Endothelin A | 4 | 2000 | 59 | 0.040 |
Why?
| | Potassium Channel Blockers | 1 | 1999 | 29 | 0.040 |
Why?
| | Male | 4 | 2018 | 55554 | 0.040 |
Why?
| | Recombinant Proteins | 3 | 2005 | 1230 | 0.040 |
Why?
| | Gene Expression Regulation, Developmental | 3 | 2010 | 800 | 0.040 |
Why?
| | Receptor, Endothelin B | 3 | 2004 | 51 | 0.040 |
Why?
| | Biological Products | 1 | 2000 | 166 | 0.040 |
Why?
| | Signal Transduction | 2 | 2010 | 4509 | 0.040 |
Why?
| | Medical Records | 1 | 1998 | 153 | 0.040 |
Why?
| | Adult | 1 | 2018 | 30528 | 0.040 |
Why?
| | Capillary Permeability | 1 | 1997 | 135 | 0.030 |
Why?
| | Pulmonary Edema | 1 | 1997 | 115 | 0.030 |
Why?
| | Pulmonary Veins | 1 | 1997 | 81 | 0.030 |
Why?
| | Pulsatile Flow | 2 | 2006 | 54 | 0.030 |
Why?
| | Acetylcholine | 3 | 2001 | 166 | 0.030 |
Why?
| | Neutrophils | 2 | 1999 | 1176 | 0.030 |
Why?
| | Analysis of Variance | 1 | 1998 | 1226 | 0.030 |
Why?
| | Echocardiography | 1 | 1997 | 553 | 0.030 |
Why?
| | Pilot Projects | 1 | 1998 | 1372 | 0.030 |
Why?
| | Pregnancy Complications, Cardiovascular | 2 | 2004 | 64 | 0.030 |
Why?
| | Blood Pressure | 3 | 2005 | 1538 | 0.030 |
Why?
| | Inflammation | 1 | 2003 | 2477 | 0.030 |
Why?
| | Hypoxia | 1 | 1998 | 957 | 0.020 |
Why?
| | Liability, Legal | 1 | 2011 | 38 | 0.020 |
Why?
| | Medical Staff, Hospital | 1 | 2011 | 75 | 0.020 |
Why?
| | Nitric Oxide Synthase Type II | 2 | 2001 | 157 | 0.020 |
Why?
| | Reference Values | 2 | 2002 | 742 | 0.020 |
Why?
| | Umbilical Cord | 1 | 2010 | 80 | 0.020 |
Why?
| | Hyperthermia, Induced | 1 | 2010 | 65 | 0.020 |
Why?
| | Uterine Artery | 1 | 2010 | 67 | 0.020 |
Why?
| | Immunologic Techniques | 2 | 1999 | 39 | 0.020 |
Why?
| | Constriction | 2 | 1999 | 45 | 0.020 |
Why?
| | Carbon Dioxide | 2 | 2000 | 218 | 0.020 |
Why?
| | Chest Wall Oscillation | 1 | 2007 | 4 | 0.020 |
Why?
| | Fetal Weight | 1 | 2007 | 52 | 0.020 |
Why?
| | Stress, Mechanical | 2 | 1999 | 445 | 0.020 |
Why?
| | Treatment Failure | 1 | 2007 | 331 | 0.020 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2007 | 270 | 0.020 |
Why?
| | Retrospective Studies | 2 | 2003 | 12542 | 0.020 |
Why?
| | Peptides, Cyclic | 2 | 1998 | 253 | 0.020 |
Why?
| | Lung Compliance | 1 | 2005 | 47 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 923 | 0.020 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2005 | 63 | 0.020 |
Why?
| | Radiography | 1 | 2007 | 812 | 0.020 |
Why?
| | Laser-Doppler Flowmetry | 1 | 2005 | 32 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2007 | 723 | 0.010 |
Why?
| | Treatment Outcome | 1 | 1998 | 9084 | 0.010 |
Why?
| | Down-Regulation | 1 | 2006 | 594 | 0.010 |
Why?
| | Parturition | 1 | 2004 | 54 | 0.010 |
Why?
| | Chronic Disease | 2 | 2002 | 1578 | 0.010 |
Why?
| | Trachea | 1 | 2005 | 224 | 0.010 |
Why?
| | Up-Regulation | 1 | 2006 | 807 | 0.010 |
Why?
| | Ventilator Weaning | 1 | 2003 | 33 | 0.010 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2002 | 61 | 0.010 |
Why?
| | Blood Flow Velocity | 1 | 2004 | 387 | 0.010 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2002 | 103 | 0.010 |
Why?
| | Time Factors | 2 | 2003 | 6112 | 0.010 |
Why?
| | Nifedipine | 1 | 2002 | 29 | 0.010 |
Why?
| | Oligonucleotides | 1 | 2002 | 137 | 0.010 |
Why?
| | Calcium Channel Blockers | 1 | 2002 | 114 | 0.010 |
Why?
| | Guanidines | 1 | 2001 | 33 | 0.010 |
Why?
| | Amidines | 1 | 2001 | 16 | 0.010 |
Why?
| | Benzylamines | 1 | 2001 | 39 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2007 | 2387 | 0.010 |
Why?
| | Calcium Channels | 1 | 2002 | 145 | 0.010 |
Why?
| | Pressure | 1 | 2002 | 214 | 0.010 |
Why?
| | Calibration | 1 | 2001 | 125 | 0.010 |
Why?
| | Body Weight | 1 | 2004 | 868 | 0.010 |
Why?
| | Quality of Life | 1 | 2011 | 2353 | 0.010 |
Why?
| | Respiration | 1 | 2001 | 179 | 0.010 |
Why?
| | Nitric Oxide Synthase Type I | 1 | 2000 | 25 | 0.010 |
Why?
| | Indazoles | 1 | 2000 | 58 | 0.010 |
Why?
| | Pulmonary Surfactants | 1 | 2000 | 99 | 0.010 |
Why?
| | Hydrocarbons, Brominated | 1 | 1999 | 5 | 0.010 |
Why?
| | Protein Precursors | 1 | 2000 | 119 | 0.010 |
Why?
| | Charybdotoxin | 1 | 1999 | 6 | 0.010 |
Why?
| | Tetraethylammonium | 1 | 1999 | 15 | 0.010 |
Why?
| | Heart Rate, Fetal | 1 | 1999 | 20 | 0.010 |
Why?
| | 4-Aminopyridine | 1 | 1999 | 21 | 0.010 |
Why?
| | Cyclic GMP | 1 | 1999 | 80 | 0.010 |
Why?
| | Isoenzymes | 1 | 1999 | 283 | 0.010 |
Why?
| | Enzyme Induction | 1 | 1997 | 84 | 0.010 |
Why?
| | Incidence | 1 | 2003 | 2311 | 0.010 |
Why?
| | Staining and Labeling | 1 | 1997 | 134 | 0.010 |
Why?
| | Congenital Abnormalities | 1 | 1997 | 73 | 0.010 |
Why?
| | Drug Evaluation, Preclinical | 1 | 1997 | 161 | 0.010 |
Why?
| | Leukocyte Count | 1 | 1997 | 293 | 0.010 |
Why?
| | Cardiomegaly | 1 | 1997 | 157 | 0.010 |
Why?
| | Algorithms | 1 | 2000 | 1466 | 0.010 |
Why?
|
|
Parker's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|